AS Insights launch new report
Interferon State of the Science and Strategic Opportunities
The world market for interferons was valued at
US$3.8 billion in 2001 and was growing at a double-digit rate. The launch
of Pegasys, Roche's new long acting formulation of its interferon alfa
Roferon is revitalizing the market for the hepatitis indication. Also the
battle between Biogen's Avonex, Schering's Betaferon and Serono's Rebif is
revitalizing the market for the multiple sclerosis indication.
The market landscape of the interferon
market is changing rapidly with new products staking new strategic
positions and old products losing market share. The market is application
dependent with different indications approved in different markets. The
impact of launch of interferon in a market is not as important as the
impact of its approval for a main-line indication. This makes interferons
a multiple niche market accessible to small players.
Interferons, State-of-the-Science &
Strategic Opportunities, is a strategic consulting report that assesses
both the technology status and the competitive landscape of the world
interferons market. The report examines both the US and the European
markets in detail, profiles leading products and companies and offers
revenue forecasts to the year 2007. The report assesses the market
attractiveness and potential and evaluates different options for market
entry.
Report Code : 0212AS3B
Report Price: US$485 Hard Copy (including
shipping & handling) US$285 PDF format (delivered by email)
Date Published: November 2002
Number of Pages: 30
To order - click
here!
